Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients diagnosed as schizophrenia or schizophrenic disorder according to DSM-IV
Patients who need new anti-psychotic drugs or need to change the medication due to aggravations of symptoms or recurrence
You may not be if
Patients with positive symptoms in whom the disorder does not correspond to schizophrenic criteria. (e.g, schizoaffective disorder)
Patients hypersensitive to the active ingredient or to other ingredients of the study drug
Prolactin-dependant tumors, pituitary gland prolactinomas and breast cancer
Pheochromocytoma or Parkinson's disease
Pregnancy or breast feeding
Current or recently withdrawn from drug abuse or alcoholism
Chronic renal failure and other internal or surgical disease which physician decides will be worsened by trial medication or that will affect the metabolism or effects of the trial medication
Patients with previous histories and clinical improvement was not seen in spite of treatment with 2 anti-psychotics for over 8 weeks
Slow heart rate of \<55bpm, low blood potassium level, congenital prolongation of the QT interval
Current treatment with a drug likely to cause markedly slow heart rate(\<55bpm), low blood potassium level, slowing of intercardiac condition or prolongation of the QT interval
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Amisulpride in Schizophrenic Patients
